Clinical Pharmacists'Participation in the Treatment of Olaparib-Induced Interstitial Pneumonia with Fever in a Patient with Prostate Cancer
Objective:To provide reference for pharmaceutical care in prostate cancer patients with olaparib-induced interstitial pneumonia and fever.Methods:The clinical pharmacists analyzed the diagnosis and treatment process of interstitial pneumonia experienced by a patient after oral administration of olaparib tablets based on the expertise on the clinical pharmacy in terms of the cause of fever and the treatment interventions of interstitial pneumonia,put forward the adjustments to the anti-tumor treatment regimen,and carried out the whole-process pharmaceutical care.Results:The dose discontinuation should be performed for the patient once upon the interstitial pneumonia,and the dose for the subsequent treatment should be adjusted according to the severity of adverse reactions.The symptoms of interstitial pneumonia of the patient were significantly improved during the participation of the clinical pharmacists in the diagnosis and treatment process.Conclusion:Although olaparib-induced interstitial pneumonia is rare,clinical pharmaceutical care should be highlighted to timely adjust medication regimen and provide symptomatic treatment,and meanwhile,the effect of drug interactions on the plasma concentration of olaparib should be paid attention to.
olaparibinterstitial pneumoniafeverinteractionpharmaceutical careprostate cancer
万方数据
维普
